知镜 Cognispect · 医学文献与研究工作台

Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea.

Baek JE, Choi A, Lee HH, Lee BI, Lee KM.
Therapeutic advances in gastroenterology · 2026-08-11 · PMID 42591914

文献摘要

Background The optimal sequencing of advanced therapy in ulcerative colitis (UC) remains unclear. Data comparing different sequencing including the use of tofacitinib as first-line therapy remain scarce. Objectives We compared the treatment persistence of two therapeutic strategies: anti-tumor necrosis factor (anti-TNF) agents to tofacitinib (A→T) versus tofacitinib to anti-TNF agents (T→A). Design We conducted a retrospective, nationwide, claims-based cohort study using data from the Korean Health Insurance Review and Assessment database. Methods We included adult UC patients initiating anti-TNF agents or tofacitinib as first-line therapy. The primary outcome was second-line treatment persistence, using Kaplan-Meier method and multivariable Cox models to estimate adjusted hazard ratios (aHRs). Propensity score matching balanced baseline characteristics. Results A total of 314 patients were included (A→T, n=273; T→A, n=41). The T→A group was younger (33.0 vs 42.0 years; P=0.02), had lower concomitant use of corticosteroids at first-line therapy (36.59% vs 65.57%; P Conclusion In Korean UC patients, switching from anti-TNF agents to tofacitinib was associated with longer second-line treatment persistence than the reverse sequence.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。